2 min read

Real-World Evidence (RWE) in China is becoming an important driver of faster and smarter drug approvals. As the healthcare industry evolves, China’s National Medical Products Administration (NMPA) is increasingly using real-world data (RWD) to support Regulatory decisions, improve patient access, and modernize drug development pathways.

Understanding Real-World Evidence in China

RWE refers to clinical evidence generated from analyzing real-world data, such as:

  • Electronic health records
  • Insurance claims databases
  • Disease registries
  • Hospital information systems
  • Adverse event reporting systems
  • Patient-generated data from wearables or mobile devices

Unlike traditional randomized clinical trials (RCTs), RWE reflects how medicines perform in routine clinical practice. This makes it valuable for regulators to assess safety, effectiveness, and long-term outcomes.

Why China Is Embracing RWE

China has actively promoted the use of RWE to accelerate innovation and meet growing healthcare needs. In 2020, the NMPA issued the Guiding Principle for Real-World Evidence to Support Drug Development and Evaluation (Trial), signaling formal acceptance of RWE in regulatory -decision processes.

China sees RWE as supportive evidence to challenges such as:

  • Limited patient populations for rare diseases
  • High costs and delays of traditional trials
  • Need for localized evidence for imported drugs
  • Post-marketing safety monitoring
  • Pediatric and elderly patient data gaps 

Key Regulatory Uses of RWE in China

1. Supporting New Drug Approvals

RWE can complement clinical trial data for innovative therapies, especially when running large RCTs is difficult or unethical.

2. Label Expansion and New Indications

Manufacturers may use RWE to seek broader indications, dosage updates, or population-specific labeling changes.

3. Post-Marketing Surveillance

RWE may be used to monitor long-term safety, effectiveness, and adverse reactions after product launch.

4. Accelerating Access in Special Zones

China’s Boao Lecheng pilot zone has been recognized for pioneering RWE use to support approvals of urgently needed imported medical products.

Challenges in Using RWE in China

Although promising, RWE in China still faces hurdles:

  • Data quality inconsistencies across hospitals
  • Fragmented healthcare databases
  • Privacy and governance concerns
  • Need for advanced analytics and causal methods
  • Standardization of evidence requirements

The NMPA emphasizes that only fit-for-purpose, reliable, and relevant data can generate acceptable RWE.

Future of RWE in China’s Pharmaceutical Market

China is expected to expand RWE use across oncology, rare diseases, biologics, and post-approval lifecycle management. For pharmaceutical companies, integrating an RWE strategy for China market access is becoming essential.

Conclusion

The role of Real-World Evidence in China’s drug Regulatory decisions is no longer optional; it is strategic. As China modernizes its pharmaceutical Regulatory framework, RWE is helping bridge evidence gaps, speed approvals, and improve patient outcomes. Companies entering China should prioritize RWE planning early in development.

Looking to navigate China’s evolving RWE Regulatory landscape with confidence? Partner with experts who understand NMPA requirements, China market access strategies, and evidence-driven approvals. Connect with Freyr to build a strong Real-World Evidence strategy that accelerates your product’s success in China.